{
  "ticker": "OSL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960011",
  "id": "02960011",
  "pages": 7,
  "price_sensitive": false,
  "date": "20250619",
  "time": "1030",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kx0lyzllhmg6.pdf",
  "summary": "### **Summary of ASX Announcement (Appendix 3G - Issue of Unquoted Securities)**  \n\n- **Issuer**: Oncosil Medical Ltd (ASX: OSL)  \n- **Security Type**: 7,500 unquoted **options** (new class, ASX code pending)  \n  - **Expiry**: 14-Jan-2030  \n  - **Exercise Price**: AUD 12.00  \n  - **Underlying Security**: OSL ordinary shares  \n- **Purpose**: Issued to a director following **shareholder approval** at EGM (29-May-2025).  \n- **Non-cash issue**: No dilutionary impact unless exercised (7,500 options insignificant vs. ~14.2m ordinary shares on issue).  \n\n**No material trading or capital structure impact identified**.",
  "usage": {
    "prompt_tokens": 1862,
    "completion_tokens": 171,
    "total_tokens": 2033,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-19T00:48:49.568249"
}